Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VIVUS, Inc.    

VIVUS, INC.

SummaryChartsNewsRatingsCalendarCompany 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

VIVUS, Inc. : New Article Discusses Treatment Options for Weight Management in People With Type 2 Diabetes

06/07/2013 | 07:28am EST


MOUNTAIN VIEW, Calif., June 7, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that a review article has been published online in TheJournal of Diabetes and Its Complications examining the importance of weight management in the treatment of type 2 diabetes. The article reviews treatment options, including lifestyle interventions, pharmacotherapy and surgery, citing Qsymia® (phentermine and topiramate extended-release) capsules CIV as a treatment option.

Authors:   Robert R. Henry, Robert Chilton, W. Timothy Garvey
Title:   "New options for the treatment of obesity and type 2 diabetes mellitus"

According to the article, studies have shown that moderate weight loss in obese patients with type 2 diabetes mellitus (T2DM) can lead to reductions in cardiometabolic risk factors such as dyslipidemia and hypertension and can have a substantial impact on mortality.

About Qsymia

Qsymia® (phentermine and topiramate extended-release) capsules CIV is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

Important Safety Information

Qsymia (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.

The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ending December 31, 2012, as amended by the Form 10-K/A filed on April 30, 2013, and periodic reports filed with the Securities and Exchange Commission.

CONTACT: VIVUS, Inc.

         Dana B. Shinbaum

         shinbaum@vivus.com


         Investor Relations:

         The Trout Group

         Brian Korb

         bkorb@troutgroup.com

         646-378-2923


         Media Relations:

         GolinHarris

         Ashley Buford

         abuford@golinharris.com

         (212) 373-6045


         Joele Frank, Wilkinson Brimmer Katcher

         Matthew Sherman | Jennifer Beugelmans

         msherman@joelefrank.com | jbeugelmans@joelefrank.com

         212-235-2665 | 212-895-8692
Source: VIVUS, Inc.

News Provided by Acquire Media

distributed by

© Publicnow 2013
All news about VIVUS, INC.
2020VIVUS : Receives Court Approval of Joint Chapter 11 Plan of Reorganization
AQ
2020VIVUS : Seeks Bankruptcy Court Approval of Second Amended Joint Chapter 11 Plan ..
AQ
2020VIVUS INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020VIVUS INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule o..
AQ
2020Health Care Flat As Growth Investors Seek Out Tech -- Health Care Roundup
DJ
2020VIVUS INC : Entry into a Material Definitive Agreement, Bankruptcy or Receiversh..
AQ
2020VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Who..
GL
2020VIVUS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
2020VIVUS INC : Entry into a Material Definitive Agreement, Regulation FD Disclosure..
AQ
2020VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.
GL
More news
Chart VIVUS, INC.
Duration : Period :
VIVUS, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
NameTitle
John P. Amos Chief Executive Officer & Director
David York Norton Chairman
Mark K. Oki Chief Financial & Accounting Officer, Senior VP
Santosh T. Varghese Chief Medical Officer & Senior Vice President
Jorge Plutzky Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VIVUS, INC.1,054.00%2
CSL LIMITED-4.25%93 519
SAMSUNG BIOLOGICS CO.,LTD.-3.63%47 194
BIOGEN INC.12.65%42 447
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.-10.55%34 810
ALEXION PHARMACEUTICALS, INC.0.29%34 293